Gilead Sciences, Inc.
Healthcare · Foster City, California · NASDAQ
Company Description
Financial Performance — 5 Years
Financial Statements
| Item | FY-4 | FY-3 | FY-2 | FY-1 | FY (latest) | Source |
|---|---|---|---|---|---|---|
| Revenue | $27.3B | $27.1B | $28.8B | $29.4B | [GILD 10-K filed 2026-02-24 · accession 0000882095-26-000006] | |
| Gross Profit | $21.6B | $20.6B | $22.5B | $23.2B | [GILD 10-K filed 2026-02-24 · accession 0000882095-26-000006] | |
| Operating Income | $11.0B | $8.8B | $10.6B | $11.7B | [GILD 10-K filed 2026-02-24 · accession 0000882095-26-000006] | |
| Operating Margin % | 40.2% | 32.6% | 36.9% | 39.7% | [GILD 10-K filed 2026-02-24 · accession 0000882095-26-000006] | |
| EBITDA | $13.2B | $11.9B | $13.6B | $14.8B | [GILD 10-K filed 2026-02-24 · accession 0000882095-26-000006] | |
| Net Income | $4.6B | $5.7B | $480.0M | $8.5B | [GILD 10-K filed 2026-02-24 · accession 0000882095-26-000006] | |
| EPS ($) | $3.64 | $4.50 | $0.38 | $6.78 | [GILD 10-K filed 2026-02-24 · accession 0000882095-26-000006] | |
| FCF | $8.3B | $7.4B | $10.3B | $9.5B | [GILD 10-K filed 2026-02-24 · accession 0000882095-26-000006] |
Economic Moat
Multiples & Valuation
| Multiple | Company | 5Y Self Avg | Delta vs 5Y Avg |
|---|---|---|---|
| P/E (TTM) [yfinance snapshot · 5Y computed 2026-04-18] | 20.3x | 75.7x (4Y) | -73.2% |
| P/E (Fwd) [yfinance forward consensus] | 14.3x | N/A | N/A |
| EV/EBITDA [yfinance snapshot · 5Y computed 2026-04-18] | 12.8x | 10.1x (4Y) | +26.8% |
| P/S [yfinance snapshot · 5Y computed 2026-04-18] | 5.8x | 4.2x (4Y) | +37.8% |
| P/B [yfinance snapshot · 5Y computed 2026-04-18] | 7.5x | 5.5x (4Y) | +36.0% |
| Div Yield [yfinance snapshot · 5Y computed 2026-04-18] | 2.38% | 3.32% (4Y) | -0.94pp |
| FCF Yield (snapshot) [computed · 2026-04-18] | 5.54% | 7.57% (4Y) | -26.8% |
5Y statistical averages computed from yfinance annual data (annual income_stmt × balance_sheet × cash_flow + price snapshots at FY-end). Source: lib/compute_5y_multiples.py · Refresh: 2026-04-18 | |||
How to Think About This Company
A full How to Think About This Company analysis for GILD — covering the essence of the business, the key variables, potential analytical pitfalls, and what distinguishes professional thinking from noise — is available within the Family Office content offering.
The difference between surface-level analysis and professional thinking often lies in the variables that are not immediately visible.
Risks & Items Under Watch
Scenario Framework
The framework below describes what conditions would need to hold in each scenario — not a price forecast.
Scenarios are descriptive, not predictive. They outline possible conditions, not expected outcomes. No probability is assigned, no scenario is preferred, and no view is offered on which one will materialize.
Analytical Lens — The Questions We Ask
In a professional company analysis, the question is not "is this good," but rather "through which lenses must the company be examined so that nothing essential is missed." Every analysis at Bakshi Finance passes through six lenses. The text below is not an evaluation — it is a mapping of the questions this analysis is designed to answer.
The analysis is based on an internal multi-factor analytical framework used in professional portfolio management. The framework maps the questions; the answers appear woven through the analysis above.
What the lens is not: there is no rating here, no score, no comparison between this company and another, and no preference. The same six questions are asked of every company on the site — the difference lies in the answers, not the tool.
This framework is intended to structure analysis, not to produce an investment conclusion.
Key Observations
This summary is not a recommendation. It is a factual list of what the analysis identified. The decision — rests with the client.
Disclosure — Family Office Format
Bakshi Finance operates as a Family Office serving qualified investors only. Mr. Yaron Bakshi held a licensed investment advisory license between 2008 and 2023. As of the publication date of this document, the firm does not hold an investment advisory license, an investment marketing license, or a portfolio management license. This document is for professional research and educational purposes only.
Nothing herein constitutes a recommendation to buy, sell, hold, or otherwise transact in any security. Nothing herein is a substitute for advice tailored to the data and needs of any particular person. Any decision is made at the sole responsibility of the investor.
Past performance is not indicative of future results.